Vyjuvek
What Vyjuvek is used for
Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Advanced therapy: a gene, cell or tissue-engineered medicine.
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Vyjuvek
- Active substance
- beremagene geperpavec
- Disease area
- Epidermolysis Bullosa Dystrophica
- Medicine group
- Preparations for treatment of wounds and ulcers
- ATC code
- D03AX16
- Marketing authorisation holder
- Krystal Biotech Netherlands B.V.
- Authorised in the EU since
- 2025
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vyjuvek used for?
Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth
What is the active substance in Vyjuvek?
Vyjuvek contains beremagene geperpavec.
Who makes Vyjuvek?
The EU marketing authorisation holder is Krystal Biotech Netherlands B.V..
Is Vyjuvek an orphan medicine?
Yes. Vyjuvek is designated an orphan medicine in the EU, for a rare disease (Epidermolysis Bullosa Dystrophica).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU